• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Antipsychotic Dosing: How High?

Antipsychotic Dosing: How High?

April 12, 2021
Paul Barkopoulos, MD.
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Paul Barkopoulos, MD. Dr. Barkopoulos has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Leucht S et al, Am J Psychiatry 2020;177(4):342–353 (published correction appears in Am J Psychiatry 2020;177(3):272)

How high should we go when dosing antipsychotics in schizophrenia? Surprisingly little is known about optimal doses. During drug development, dosing is estimated from animal studies, but more detailed studies in humans are rare. A recent meta-analysis of 68 studies examined dose-response relationships in randomized controlled trials of antipsychotic medications for schizophrenia and schizoaffective disorder. The outcome of interest was the dose producing a 95% reduction in symptoms (ED95).

For many medications, the ED95 dose differed greatly from the FDA-recommended maximum. For example, aripiprazole’s ED95 was 11.5 mg/day, in contrast to the 30 mg/day maximum licensed dose. For numerous medications, including olanzapine (for positive symptoms), clozapine, and lurasidone, the dose response curves did not plateau, implying that dose escalation beyond the ED95 may still be efficacious. Other medications, such as quetiapine, cariprazine, and brexpiprazole, showed a clear plateau in dose response—implying no extra benefit of further escalation. Several medications showed a bell-shaped dose response curve, including haloperidol, risperidone, olanzapine (for negative symptoms), and aripiprazole, implying a negative response with a higher dose.

CHPR’s Take
For most antipsychotics, the ED95 is slightly lower than the FDA maximum dose. For some commonly used agents, such as aripiprazole and quetiapine, we may be dosing patients more aggressively than needed. Others may need to be tailored to the ­individual.
Table: Dose-Response Relationships for Antipsychotic Drugs

Table: Dose-Response Relationships for Antipsychotic Drugs

(Click to view full-size PDF.)
Hospital Psychiatry
KEYWORDS antipsychotics free_articles research-update
Paul Barkopoulos, MD.

QT Intervals in Psychiatric Practice

More from this author
www.thecarlatreport.com
Issue Date: April 12, 2021
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Psychiatric Emergencies, CHPR, Jan/Feb/Mar 2021
Introducing The Carlat Hospital Psychiatry Report (CHPR)
Intranasal Esketamine: New Hope for Suicidal Patients?
Serotonin Syndrome Versus NMS
Deliberate Foreign Body Ingestion
Combination Treatment for Schizophrenia
Antipsychotic Dosing: How High?
Welcoming Our New Editor-in-Chief
DOWNLOAD NOW
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    (PRE-ORDER) Treating Alcohol Use Disorder—A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto104192710.jpg
    Hospital Psychiatry

    Management of Depression and Neurocognitive Impairment in Patients With HIV

    Strategies for the evaluation and management of HIV-associated mood and cognitive changes and potential drug interactions between psychiatric and antiretroviral medications. 

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.